Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACER

ACER - Acer Therapeutics Inc Stock Price, Fair Value and News

0.66USD Delayed
Watchlist

Market Summary

USD0.66
Delayed

ACER Stock Price

View Fullscreen

ACER RSI Chart

ACER Valuation

Market Cap

16.1M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

12.81

Price/Free Cashflow

-0.43

ACER Price/Sales (Trailing)

ACER Profitability

Return on Equity

-36.7%

Return on Assets

-346.28%

Free Cashflow Yield

-231.27%

ACER Fundamentals

ACER Revenue

Revenue (TTM)

1.3M

ACER Earnings

Earnings (TTM)

-48.5M

Earnings Growth (Yr)

-194.22%

Earnings Growth (Qtr)

-82.08%

Breaking Down ACER Revenue

Last 7 days

-8.0%

Last 30 days

5.3%

Last 90 days

10.0%

Trailing 12 Months

-35.0%

How does ACER drawdown profile look like?

ACER Financial Health

Current Ratio

0.1

Debt/Equity

0.02

Debt/Cashflow

-11.68

ACER Investor Care

Shares Dilution (1Y)

49.41%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210001.3M
20200000
20190000
20180000
20170000
20162.9M2.9M2.9M2.9M
20151.3M1.7M2.1M2.6M
20141.4M1.4M1.3M1.3M
20130001.3M

Tracking the Latest Insider Buys and Sells of Acer Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 17, 2023
davis jefferson e
back to issuer
-
-
-71,645
chief business officer
Nov 17, 2023
schelling chris
back to issuer
-
-
-2,712,530
president and ceo
Nov 17, 2023
palmin harry s
back to issuer
-
-
-125,000
chief financial officer
Nov 17, 2023
joseph donald
back to issuer
-
-
-14,285
see remarks
Nov 17, 2023
dunn john michael
back to issuer
-
-
-27,380
-
Nov 17, 2023
aselage steve
back to issuer
-
-
-483,741
-
Nov 29, 2022
aselage steve
bought
500,000
1.22
409,836
-
Nov 29, 2022
schelling chris
bought
1,000,000
1.22
819,672
president & ceo
Dec 10, 2021
aselage steve
bought
16,287
2.04
7,984
-
Dec 09, 2021
aselage steve
bought
4,334
2.15
2,016
-

1–10 of 17

Which funds bought or sold ACER recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Nantahala Capital Management, LLC
sold off
-100
-748,454
-
-%
Feb 14, 2024
VANGUARD GROUP INC
sold off
-100
-386,387
-
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-
-
-%
Feb 14, 2024
CSS LLC/IL
sold off
-100
-9,256
-
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-21,624
-
-%
Feb 14, 2024
Tudor Investment Corp Et Al
sold off
-100
-755,538
-
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
sold off
-100
-2,611
-
-%
Feb 14, 2024
STATE STREET CORP
sold off
-100
-43,786
-
-%
Feb 13, 2024
MORGAN STANLEY
sold off
-100
-1.00
-
-%

1–10 of 32

Are Funds Buying or Selling ACER?

Are funds buying ACER calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACER
No. of Funds

Unveiling Acer Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 30, 2023
tvm life science ventures vi lp
1.1%
248,756
SC 13D/A
Feb 14, 2023
nantahala capital management, llc
7.5%
1,226,191
SC 13G/A
Dec 02, 2022
schelling chris
16.0%
2,858,995
SC 13D/A
Feb 14, 2022
nantahala capital management, llc
6.3%
901,290
SC 13G/A
Feb 12, 2021
nantahala capital management, llc
8.1%
989,755
SC 13G/A
Aug 06, 2020
hirschman orin
8.5%
982,446
SC 13G/A
Aug 03, 2020
schelling chris
17.3%
1,951,369
SC 13D/A
May 19, 2020
hirschman orin
5.4%
552,040
SC 13G
Feb 13, 2020
vivo opportunity, llc
0%
0
SC 13G/A
Feb 12, 2020
nantahala capital management, llc
9.8%
990,655
SC 13G/A

Recent SEC filings of Acer Therapeutics Inc

View All Filings
Date Filed Form Type Document
Nov 30, 2023
15-12G
15-12G
Nov 24, 2023
EFFECT
EFFECT
Nov 24, 2023
EFFECT
EFFECT
Nov 20, 2023
POS AM
POS AM
Nov 20, 2023
10-Q
Quarterly Report
Nov 20, 2023
25-NSE
25-NSE
Nov 20, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading

Peers (Alternatives to Acer Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Acer Therapeutics Inc News

Latest updates
Marketscreener.com38 hours ago
Pharmaceutical Technology3 months ago

Acer Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q42018Q3
Revenue0.5%372370368367365363362360--900----------
Costs and Expenses-13,250---5,239----------------
Operating Expenses-100.0%-4,2944,9895,2635,2397,0657,0474,7803,2793,6305,520--------8,7004,107
  S&GA Expenses64.4%4,6912,8542,5682,6182,5573,6383,8763,0741,8432,2693,514--------3,3871,729
  R&D Expenses5.7%1,5221,4412,4212,6452,6823,4273,1721,7051,4351,3612,006--------5,3122,378
Interest Expenses-100.0%-677322------------------
Net Income-82.1%-14,731-8,090-16,280-9,384-5,006-2,667-9,179-4,420-3,273-3,069-4,611---------8,496-3,965
Net Income Margin-25.1%-38.48*-30.76*-26.46*-20.82*-16.88*-15.51*-15.83*-12.20*-5.92*-6.83*-7.76*-7.88*-7.51*--------
Free Cashflow-161.3%-14,382-5,504-9,020-8,433-9,092-9,854-3,042-1,440-7,9766,2283,000-3,888-4,500--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-4.4%14.0015.0016.0012.0015.0023.0031.0036.0033.0040.0045.0015.0015.0015.0016.0021.0026.0033.0041.0051.0055.00
  Current Assets-9.1%6.007.008.004.007.0015.0023.0028.0025.0032.0036.006.007.006.008.0013.0017.0024.0033.0043.0047.00
    Cash Equivalents-62.5%1.002.006.002.006.0014.0021.0013.0014.0022.0016.006.006.006.007.0012.0016.0023.0032.0042.0046.00
  Inventory0%5.005.000.00------------------
  Net PPE-24.5%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%8.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.008.00
Liabilities28.9%62.0048.0042.0028.0028.0032.0042.0038.0030.0035.0037.006.005.004.002.003.003.005.003.006.002.00
  Current Liabilities42.1%62.0043.0038.0019.0021.0018.0028.0029.0030.0035.0032.006.004.003.002.003.002.005.003.006.00-
Shareholder's Equity0.2%1321321311241191181141132.005.007.008.0011.0011.0014.0018.0023.0028.0038.0045.0053.00
  Retained Earnings-8.9%-179-165-157-140-131-126-123-114-110-106-103-99.14-92.90-86.97-81.20-76.25-71.09-65.84-54.80-46.83-38.34
  Additional Paid-In Capital0.2%13213213112411911811411311211211110710398.0095.0095.0094.0093.0093.0092.0091.00
Shares Outstanding0%24.0024.0023.0020.0016.0015.0014.0014.0014.0014.0014.0013.0012.00--------
Float------20.00---35.00---21.00---22.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-161.3%-14,382-5,504-9,017-8,298-9,087-9,852-3,013-1,420-7,9576,2383,005-3,879-4,447-3,600-5,100-3,991-7,375-8,389-9,750-4,590-4,750
  Share Based Compensation-10.5%233260286446460461474533600595559466487604667662564715672387353
Cashflow From Investing----3.07-135-4.90-2.00-28.93-20.49-19.24-9.90-5.32-8.67----52.899.00-46.02-88.94-10.70-69.80
Cashflow From Financing1881.0%13,42467813,0724,3851,0013,52411,132---7,1393,4934,726------87.0042,662

ACER Income Statement

2023-09-30
Condensed Statements of Operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Product revenue, net$ 371,790 $ 371,790 
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:ProductMember us-gaap:ProductMember 
Operating costs and expenses :    
Cost of product revenue$ 83,805 $ 83,805 
Payments to collaboration partner6,952,802 6,952,802 
Research and development (net of collaboration funding of $0 and $2,178,078 in the three months ended September 30, 2023 and 2022, respectively, and of $1,318,482 and $6,826,080 in the nine months ended September 30, 2023 and 2022, respectively)1,522,161$ 2,681,6805,383,998$ 9,280,092
Selling, general and administrative (net of collaboration funding of $0 and $1,432,889 in the three months ended September 30, 2023 and 2022, respectively, and of $2,547,291 and $7,062,766 in the nine months ended September 30, 2023 and 2022, respectively)4,690,9602,557,37010,112,90210,071,044
Total operating costs expenses13,249,7285,239,05022,533,50719,351,136
Loss from operations(12,877,938)(5,239,050)(22,161,717)(19,351,136)
Other income (expense), net:    
Costs of debt issuance (122,400)(577,225)(1,490,594)
Loss on extinguishment of debt  (8,541,494) 
Changes in fair value of debt instruments (loss) gain(1,722,496)324,550(6,740,719)4,091,610
Interest and other (expense) income, net(133,157)19,431(1,059,304)(122,641)
Foreign currency transaction gain (loss)2,32410,524(22,234)19,776
Total other (expense) income, net(1,853,329)232,105(16,940,976)2,498,151
Net loss$ (14,731,267)$ (5,006,945)$ (39,102,693)$ (16,852,985)
Net loss per share - basic$ (0.60)$ (0.31)$ (1.68)$ (1.11)
Weighted average common shares outstanding - basic24,463,72616,089,01923,254,25315,230,839
Net loss per share - diluted$ (0.60)$ (0.31)$ (1.68)$ (1.13)
Weighted average common shares outstanding - diluted24,463,72616,089,01923,254,25317,085,784

ACER Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 594,659$ 2,329,218
Inventory5,202,597 
Prepaid expenses328,918759,292
Deferred financing costs 408,000
Other current assets14,63820,188
Total current assets6,140,8123,516,698
Property and equipment, net40,976214,578
Other assets:  
Goodwill7,647,2677,647,267
Other non-current assets173,010245,683
Total assets14,002,06511,624,226
Current liabilities:  
Accounts payable7,009,0663,813,280
Accrued expenses5,066,5493,657,394
Deferred collaboration funding, current 8,412,971
Accrued payment to collaboration partner1,500,000 
Schelling Promissory Note payable to an officer1,016,766 
Other current liabilities743,856741,425
Convertible note payable, current, at fair value14,635,200 
Term Loans payable, current, at fair value18,152,3442,326,630
Zevra bridge loan payable13,546,557 
Total current liabilities61,670,33818,951,700
Term Loans payable, non-current, at fair value 3,240,601
Convertible note payable, at fair value 6,047,532
Other non-current liabilities76,689145,665
Total liabilities61,747,02728,385,498
Commitments and Contingencies (Note 9)
Stockholders’ deficit:  
Preferred stock, $0.0001 par value; authorized 10,000,000 shares; none issued and outstanding 
Common stock, $0.0001 par value; authorized 150,000,000 shares; 24,463,726 and 19,624,280 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively2,4461,962
Additional paid-in capital132,102,554123,984,035
Accumulated deficit(179,849,962)(140,747,269)
Total stockholders’ deficit(47,744,962)(16,761,272)
Total liabilities and stockholders’ deficit$ 14,002,065$ 11,624,226
ACER
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
 CEO
 WEBSITEwww.acertx.com
 EMPLOYEES30

Acer Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Acer Therapeutics Inc? What does ACER stand for in stocks?

ACER is the stock ticker symbol of Acer Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acer Therapeutics Inc (ACER)?

As of Mon Nov 20 2023, market cap of Acer Therapeutics Inc is 16.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACER stock?

You can check ACER's fair value in chart for subscribers.

What is the fair value of ACER stock?

You can check ACER's fair value in chart for subscribers. The fair value of Acer Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acer Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACER so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acer Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACER is over valued or under valued. Whether Acer Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acer Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACER.

What is Acer Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 20 2023, ACER's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 12.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acer Therapeutics Inc's stock?

In the past 10 years, Acer Therapeutics Inc has provided -0.421 (multiply by 100 for percentage) rate of return.